Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
48 participants
INTERVENTIONAL
2023-04-01
2027-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
lutéine
10 mg/d lutéine
luteine
luteine
zeaxanthine
10 mg/d zéaxanthine
zeaxanthine
zeaxanthine
lutéine and zeaxanthine
10 mg/d lutéine + 2 mg/d zéaxanthine
luteine and zeaxanthine
luteine and zeaxanthine
placebo
same excipient used in the other arms with a carmine red dye
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
luteine and zeaxanthine
luteine and zeaxanthine
luteine
luteine
zeaxanthine
zeaxanthine
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Exclusive enteral nutrition that is intended to be continued for at least 6 more months.
* No XANTH supplementation in the last 6 months.
* Able to sit up to allow visual examinations to be performed
* Sufficient understanding to perform visual examinations, at the discretion of the physician
* Written consent signed by the patient or agreement of their carer, trusted person, relative, family for patients with cognitive impairment (assessed using an MMS test). A patient with an MMSE test result ≤ 24 will be considered as having cognitive disorders.
Exclusion Criteria
* Visually impaired patient: patient unable to read text (font size 11) at close range, with visual correction if the patient usually wears it
* Unoperated cataracts in both eyes
* Pregnant or breastfeeding woman
* Patient under legal protection: guardianship or curatorship
* Participation in other research in the same field of dietary supplementation, which may interfere with the results of this research.
* Absence of XANTH (lutein and zeaxanthin) deficiency\* in the blood sample taken at inclusion.
* Physical, ophthalmological or cognitive characteristics, evaluated at the Quinze-Vingt ophthalmological examination, which do not allow a reliable measurement of MPOD or of all the settings of visual function.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP220293
Identifier Type: -
Identifier Source: org_study_id